Navigation Links
Micromet, Inc. Reports First Quarter 2009 Financial Results
Date:5/6/2009

A second BiTE antibody, MT110, is being tested in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Its human monoclonal antibody adecatumumab, or MT201, also binds to EpCAM and is being developed under a collaboration with Merck Serono. The current clinical development of this antibody includes a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is being developed in a phase 1 clinical trial for the treatment of patients with cancer.

In addition to the four antibodies described above, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor, or GM-CSF, which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Nycomed has filed a clinical trial application and is expected to commence a phase 1 clinical trial of MT203 in the first half of 2009. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with MT228, a glycolipid-binding human antibody for the treatment of melanoma. Micromet also has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target.

Micromet's preclinical product pipeline includes severa
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Micromet, Inc. Reports First Quarter 2008 Financial Results
2. Micromet, Inc. Reports Second Quarter 2008 Financial Results
3. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. Haemacure Reports Third Quarter 2007 Results
6. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
7. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
8. MDS Reports Third Quarter 2007 Results
9. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... With chronic respiratory disorders, method cuts death risk, study ... with chronic respiratory disorders who receive early non-invasive ventilation ... likely to suffer respiratory failure or die, a Spanish ... on mechanical ventilation. All of them had high levels ...
... , , , , ... KAD ), a leading provider of home care, medical staffing, and pharmacy services ... ended June 30, 2009. , , For the ... with $26.8 million for the same period last year. Arcadia reported a ...
... The Gilchrist Institute for the Achievement Sciences, an economic ... health care reform aimed at members of Congress and the ... Gilchrist Institute Director Dr. Robert Flower states, "We are challenging ... the application that needs reform and the administration that needs ...
... 13 Insmed Inc. (Nasdaq: INSM ), a biopharmaceutical ... June 30, 2009. , , Revenues for the ... $2.7 million for the corresponding period in 2008. The increase ... IPLEX(TM) myotonic muscular dystrophy ("MMD") clinical trial recorded in the most ...
... ... introduced the supplement NourishLife speak™ which combines omega-3 and vitamin E ... A recent study published in the July issue of Alternative ... apraxia taking a combination of omega-3 and vitamin E noted significant ...
... ... proud to announce the September 1 opening of its newest office in ... population from Hoboken, Jersey City and the Newport area and our physicians ... services. The Hoboken office is partly the result of a merger with ...
Cached Medicine News:Health News:Ventilation After Breathing Tube Removal May Alter Outcomes 2Health News:Arcadia Resources Announces First Quarter Results 2Health News:Arcadia Resources Announces First Quarter Results 3Health News:Arcadia Resources Announces First Quarter Results 4Health News:Arcadia Resources Announces First Quarter Results 5Health News:Arcadia Resources Announces First Quarter Results 6Health News:Arcadia Resources Announces First Quarter Results 7Health News:Arcadia Resources Announces First Quarter Results 8Health News:Arcadia Resources Announces First Quarter Results 9Health News:Arcadia Resources Announces First Quarter Results 10Health News:Arcadia Resources Announces First Quarter Results 11Health News:Arcadia Resources Announces First Quarter Results 12Health News:Arcadia Resources Announces First Quarter Results 13Health News:Arcadia Resources Announces First Quarter Results 14Health News:Arcadia Resources Announces First Quarter Results 15Health News:Institute Chastises Congress on Health Care Reforms, Offers Five-Point Program for Reducing Health Care Costs by 50% 2Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 2Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 3Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 4Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 5Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 6Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 7Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 8Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 9Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 2Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 3Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 4Health News:ENT and Allergy Opens New Office in Hoboken, New Jersey…Practice Achieves Milestone by Bringing on its 100th Physician 2Health News:ENT and Allergy Opens New Office in Hoboken, New Jersey…Practice Achieves Milestone by Bringing on its 100th Physician 3Health News:ENT and Allergy Opens New Office in Hoboken, New Jersey…Practice Achieves Milestone by Bringing on its 100th Physician 4
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless ... Robert F. Doman , Executive Chairman and Interim ... Noble Financial Capital Markets, Tenth Annual Equity Conference. ... corporate presentation to prospective corporate partners and investors ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ... price of $2.92 per share, net to the seller ...
(Date:1/14/2014)... , Jan. 14, 2014 ... ), a leading innovator of less invasive, miniaturized ... of advanced heart failure, today announced that it ... will be approximately $53 million, bringing expected full-year ... "Our full-year revenue growth of 87% for 2013 ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... up to 10 LPM of oxygen reducing the ... The M10 is engineered to reduce the cost ... has fewer parts than any other concentrator on ... help you to reduce expenditure on accessories and ...
... important to have a choice that fits your ... with innovative excellence, offers two great choices! Introducing ... value packed conservers., ,With its single AA ... hours a day for 3 to 4 weeks ...
... Get the equivalent of 7.5 liters out ... will you need two machines for your high-flow ... OXYMIZER Disposable Oxygen-Conserving Devices function like standard conservers, ... flow of oxygen required to saturate a patient. ...
The 24-Hour Oxygen Conserver....
Medicine Products: